Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $482.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ritu Baral has given his Buy rating due to a combination of factors including Amvuttra’s strong commercial performance and Alnylam’s rapid transition to sustained profitability. Amvuttra delivered robust quarter‑over‑quarter and year‑over‑year growth, driving both GAAP and non‑GAAP earnings into positive territory and demonstrating durable demand in the transthyretin (TTR) franchise.
Ritu Baral’s rating is based on management’s outlook for continued revenue expansion, supported by increasing cardiomyopathy penetration, geographic rollouts, and high treatment adherence, alongside sizable collaboration and royalty streams. In addition, the company’s guidance for double‑digit compound annual revenue growth through 2030 and the path to an attractive non‑GAAP operating margin underpin confidence in long‑term value creation, justifying the Buy recommendation.
According to TipRanks, Baral is a top 100 analyst with an average return of 39.7% and a 53.91% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, Praxis Precision Medicines, and Alnylam Pharma.